The global GLP-1 analogues market is experiencing unprecedented growth, driven by the rising prevalence of type 2 diabetes, obesity, and associated cardiovascular disorders. Valued at US$ 51.6 billion in 2024, the market is projected to expand significantly and reach US$ 211.8 billion by 2035, growing at a robust CAGR of 13.7% from 2025 to 2035. This rapid growth reflects the...